 |
Corporate News
06-Oct-23
|
|
|
|
|
|
|
|
|
|
|
|
Biocon partners with Juno Pharmaceuticals
|
|
To manufacture and supply Liraglutide in Canadian market
|
|
|
|
|
|
Biocon announced the signing of a partnership agreement with
Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
|
|
|
|
Previous News |
Biocon Ltd spurts 4.01%, rises for fifth straight session
(
Hot Pursuit
-
26-Apr-24
13:00
)
|
|
|
Biocon appoints Interim CFO
(
Corporate News
-
11-Jun-24
17:16
)
|
|
|
Biocon Ltd rises for third straight session
(
Hot Pursuit
-
15-Feb-24
13:05
)
|
|
|
Biocon inks pact with Juno Pharma for commercialization of Liraglutide
(
Hot Pursuit
-
09-Oct-23
10:11
)
|
|
|
Biocon Ltd up for fifth session
(
Hot Pursuit
-
06-Feb-24
13:00
)
|
|
|
Biocon gets nod from SAHPRA for Tacrolimus capsules
(
Hot Pursuit
-
20-Apr-24
15:36
)
|
|
|
ICICI Bank board to mull fund raising proposal
(
Hot Pursuit
-
20-Apr-24
14:40
)
|
|
|
Biocon appoints director
(
Corporate News
-
30-Jul-22
12:52
)
|
|
|
Biocon redeems commercial paper of Rs 2250 cr
(
Corporate News
-
23-Feb-23
10:14
)
|
|
|
Biocon acquires facility of Eywa Pharma in US for $7.7 mln
(
Hot Pursuit
-
02-Sep-23
14:59
)
|
|
|
Biocon Biologics set to introduce YESAFILI®, a proposed biosimilar to EYLEA® in Canadian market
(
Corporate News
-
04-Mar-24
09:30
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|